BioSpace News Archive

PolyBio Research Foundation has announced a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin , co-founder of Ethereum.

Sanofi, a leader in diabetes care, launched “The 1 Pledge” movement, a nationwide education campaign urging families to get screened for type 1 diabetes so that those who will eventually be affected by the disease can begin to prepare as soon as possible.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2023.

CareDx, Inc. announced that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson.

Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, reported its financial results for the quarter ended September 30, 2023 and updated its financial guidance for the year ending December 31, 2023.

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, reported financial results for the third quarter ended September 29, 2023.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 by conference call on Wednesday, November 8, 2023 at 4:30 PM ET.

NANOBIOTIX announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering reserved to specified categories of investors consisting of an offering of its American Depositary Shares.